According to Brazilian media outlet Conselho, the Brazilian National Health Surveillance Agency (Anvisa) is currently soliciting public opinions on a new draft regulation for e-cigarettes. The consultation and open voting activities will conclude on February 9, 2024.
Brazil's health regulatory agency, Anvisa, approved a proposal for Consultative Public Voting (CP) in December 2023. The proposal, identified as number 1.222/2023, primarily addresses regulations for electronic cigarette devices (DEFs). This new resolution will replace the existing regulations that have been enforced since 2009.
The main points of this proposal include the continued prohibition of the production, import, sale, distribution, storage, and transportation of e-cigarettes, including all types of e-cigarettes. It also explicitly states that any form of public promotion for these products is prohibited, regardless of whether it is targeted towards consumers.
The Brazilian National Health Council (CNS) believes that the proposal by Anvisa is crucial and will contribute to improving the health and well-being of the Brazilian people. They support the revision of current regulations and consider this adjustment to align with the recommendations of the World Health Organization's Framework Convention on Tobacco Control and scientific evidence.
All individuals concerned about this matter have the opportunity to participate and provide feedback by February 9, 2024. Participants can provide simplified feedback by using the dedicated electronic form available on the official Anvisa website, indicating their support for the proposal, or they can provide detailed comments on each clause of the proposal.
The objective of Anvisa's public consultation is to make decisions regarding specific regulations based on solid evidence. Its main goal is to gather critical and well-founded evaluations of the suggested regulations from different sectors of society. Once all suggestions have been received, Anvisa will review all feedback and release a report on the public consultation on its official website.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
